Enhanced Ability of Oligomeric Nanobodies Targeting MERS Coronavirus Receptor-Binding Domain

Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV), an infectious coronavirus first reported in 2012, has a mortality rate greater than 35%. Therapeutic antibodies are key tools for preventing and treating MERS-CoV infection, but to date no such agents have been approved for treatment of...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Lei, Tai, Wanbo, Li, Jiangfan, Chen, Yuehong, Gao, Yaning, Li, Junfeng, Sun, Shihui, Zhou, Yusen, Du, Lanying, Zhao, Guangyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6410414/
https://www.ncbi.nlm.nih.gov/pubmed/30791410
http://dx.doi.org/10.3390/v11020166

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6410414/
https://www.ncbi.nlm.nih.gov/pubmed/30791410
http://dx.doi.org/10.3390/v11020166

Ejemplares similares